October 2021 Editor's pick Jolien Blokken

Overall survival benefit with tebentafusp in metastatic uveal melanoma

Patients with HLA-A*02:01–positive previously untreated metastatic uveal melanoma generally respond poor to systemic treatment and face a poor prognosis. However, treatment with tebentafusp, a soluble T-cell receptor and CD3-directed bispecific fusion protein, now demonstrated to result in significantly longer overall survival than the investigator’s choice of treatment with pembrolizumab, ipilimumab, or dacarbazine… 

Read more

Extended therapy with letrozole as adjuvant treatment of postmenopausal breast cancer patients

In postmenopausal patients with breast cancer who received 2–3 years of tamoxifen, extended treatment with 5 years of letrozole resulted in a significant improvement in disease-free survival compared with the standard 2–3 years of letrozole. As such, the use of an aromatase inhibitor for 5 years after initial tamoxifen for 2–3 years should be considered as an optimal standard treatment for this patient population…

Read more

Prophylactic cranial irradiation with or without hippocampal avoidance for small-cell lung cancer

The phase III PREMER trial was designed to investigate the neurotoxicity of prophylactic cranial irradiation (PCI) and the benefits and risks of sparing the hippocampus in patients with small-cell lung cancer (SCLC) who receive PCI. Avoidance of the hippocampus during PCI better preserves neurocognitive function, while observing no difference with standard PCI in terms of quality of life, intracranial relapse, and overall survival…

Read more

Continuous versus intermittent extended adjuvant letrozole for breast cancer

Among postmenopausal women with hormone-receptor positive breast cancer, the final analysis of the SOLE study, with median follow-up of 7 years, confirmed the previous results of the trial and demonstrated that intermittent letrozole treatment did not show superiority, in terms of disease-free survival, compared with continuous therapy in the extended adjuvant setting…

Read more

Pembrolizumab as a promising treatment option for cutaneous squamous cell carcinoma

In the second interim analysis of the phase II Keynote-629 study, the robust antitumour activity of pembrolizumab was confirmed in patients with both locally advanced and relapsed/metastatic cutaneous squamous cell carcinoma. In addition, pembrolizumab demonstrated to be durable without unexpected safety signals…

Read more